[HTML][HTML] Noncanonical NF-κB signaling upregulation in inflammatory bowel disease patients is associated with loss of response to anti-TNF agents
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents
VQ Nguyen, K Eden, HA Morrison… - … and Fibrosis in the …, 2023 - books.google.com
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
[HTML][HTML] Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents
VQ Nguyen, K Eden, HA Morrison… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
Noncanonical NF-kappa B Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents
VQ Nguyen, K Eden, HA Morrison, MB Sammons… - 2021 - vtechworks.lib.vt.edu
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents
VQ Nguyen, K Eden, HA Morrison… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents.
VQ Nguyen, K Eden, HA Morrison… - Frontiers in …, 2021 - europepmc.org
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
[PDF][PDF] Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated with Loss of Response to Anti-TNF Agents
VQ Nguyen, HA Morrison… - … of Noncanonical NF-κB …, 2023 - vtechworks.lib.vt.edu
Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …
and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel …